{
  "ptid_time": "023_S_0042_2006-11-09",
  "img_path": "/data/qiuhui/data/adni/images/023_S_0042/2006-11-09/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 52,933 mm³, 37.4% above the reference mean. With a Z-score of 0.90 (81.5th percentile), this represents normal volume ; hippocampal volume measures 3,858 mm³, 49.0% below the reference mean. With a Z-score of -4.78 (0.0th percentile), this represents profound atrophy; whole brain volume measures 920,277 mm³, 14.7% below the reference mean. With a Z-score of -1.91 (2.8th percentile), this represents moderate atrophy; entorhinal cortex volume measures 2,773 mm³, 32.4% below the reference mean. With a Z-score of -2.20 (1.4th percentile), this represents significant atrophy; fusiform gyrus volume measures 17,696 mm³, 6.1% below the reference mean. With a Z-score of -0.52 (30.3th percentile), this represents normal volume ; middle temporal gyrus volume measures 15,444 mm³, 27.6% below the reference mean. With a Z-score of -2.48 (0.7th percentile), this represents significant atrophy. ",
  "text_data": "Age is 73.8 years. Gender is Male. Education: 18 years. MMSE: 24.0. Logical Memory: 0.0. APOEε4 alleles: 0.0. Biomarker levels: Amyloid beta: 766.50 pg/mL (normal ); Total tau: 205.40 pg/mL (normal ); Phosphorylated tau: 18.40 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows profound hippocampal atrophy, significant entorhinal cortex and middle temporal gyrus atrophy, and moderate whole-brain atrophy, which are strongly suggestive of neurodegeneration. However, CSF biomarkers (Aβ, T-tau, P-tau) are normal, and the MMSE score of 24 is borderline, making this a complex case.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely non-AD etiology given normal biomarkers)  \n**Confidence:** **Medium** (due to conflicting imaging and biomarker findings)  \n\n*Note: Given the severe hippocampal atrophy, progressive MCI or early dementia cannot be ruled out, but normal CSF biomarkers make typical Alzheimer’s pathology less likely. Further clinical correlation (e.g., FDG-PET, neuropsychological testing) would help clarify.*",
  "timestamp": "2025-07-26T02:28:16.499788"
}